Thu, 01 Feb 2024 17:26
Journal List PLoS One PMC10441795 As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more:
PMC Disclaimer |
PMC Copyright Notice PLoS One. 2023; 18(8): e0288138.
Raphael Josef Eberle,
Conceptualization
,
Formal analysis
,
Investigation
,
Methodology
,
Supervision
,
Validation
,
Writing '' original draft
,
Writing '' review & editing
,
1,2,* M´nika Aparecida Coronado,
Investigation
,
Methodology
,
Writing '' review & editing
,
1 Ian Gering,
Formal analysis
,
Methodology
,
Validation
,
Writing '' review & editing
,
1 Simon Sommerhage,
Methodology
,
Validation
,
Writing '' review & editing
,
1 Karolina Korostov,
Methodology
,
Writing '' review & editing
,
1 Anja Stefanski,
Formal analysis
,
Methodology
,
Validation
,
Writing '' review & editing
,
3 Kai St¼hler,
Resources
,
Writing '' review & editing
,
3 Victoria Kraemer-Schulien,
Formal analysis
,
Methodology
,
Validation
,
Writing '' review & editing
,
1 Lara Bl¶meke,
Methodology
,
Writing '' review & editing
,
1,2 Oliver Bannach,
Resources
,
Writing '' review & editing
,
1,2,4 and
Dieter Willbold,
Resources
,
Writing '' review & editing
1,2,5Raphael Josef Eberle1Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum J¼lich, J¼lich, Germany
2Institute of Physical Biology, Heinrich-Heine-University D¼sseldorf, D¼sseldorf, Germany
M´nika Aparecida Coronado1Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum J¼lich, J¼lich, Germany
Ian Gering1Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum J¼lich, J¼lich, Germany
Simon Sommerhage1Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum J¼lich, J¼lich, Germany
Karolina Korostov1Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum J¼lich, J¼lich, Germany
Anja Stefanski3Molecular Proteomics Laboratory (MPL), BMFZ, Heinrich-Heine-University D¼sseldorf, D¼sseldorf, Germany
Kai St¼hler3Molecular Proteomics Laboratory (MPL), BMFZ, Heinrich-Heine-University D¼sseldorf, D¼sseldorf, Germany
Victoria Kraemer-Schulien1Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum J¼lich, J¼lich, Germany
Lara Bl¶meke1Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum J¼lich, J¼lich, Germany
2Institute of Physical Biology, Heinrich-Heine-University D¼sseldorf, D¼sseldorf, Germany
Oliver Bannach1Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum J¼lich, J¼lich, Germany
2Institute of Physical Biology, Heinrich-Heine-University D¼sseldorf, D¼sseldorf, Germany
4attyloid GmbH, D¼sseldorf, Germany
Dieter Willbold1Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum J¼lich, J¼lich, Germany
2Institute of Physical Biology, Heinrich-Heine-University D¼sseldorf, D¼sseldorf, Germany
5JuStruct: J¼lich Centre for Structural Biology, Forschungszentrum J¼lich, J¼lich, Germany
Maria Gasset, Editor
1Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum J¼lich, J¼lich, Germany
2Institute of Physical Biology, Heinrich-Heine-University D¼sseldorf, D¼sseldorf, Germany
3Molecular Proteomics Laboratory (MPL), BMFZ, Heinrich-Heine-University D¼sseldorf, D¼sseldorf, Germany
4attyloid GmbH, D¼sseldorf, Germany
5JuStruct: J¼lich Centre for Structural Biology, Forschungszentrum J¼lich, J¼lich, Germany
Consejo Superior de Investigaciones Cientificas, SPAIN
Corresponding author.
Competing Interests: The authors have declared that no competing interests exist.
Received 2023 Mar 16; Accepted 2023 Jun 20.
This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Supplementary MaterialsS1 Fig: SDS PAGE of 2N4R tau purification. M: Protein marker; 1: Supernatant after cell disruption; 2: Supernatant after ammonium sulfate precipitation; 3: Pellet after ammonium sulfate precipitation solved in buffer 2; 4: SN after centrifugation pellet solved in buffer 2; 5: Pellet solved in ddH
2O and 2 mM TCEP; 6: Pellet was solved in buffer 3; 7: SN after centrifugation pellet solved in buffer 3; 8: Sample after dialysis against buffer 4.
(TIF)
GUID: 6097DEB1-FC12-49D4-AEF3-8EFA8082FC6D
S2 Fig: Characterization of 2N4R tau.
A: SDS PAGE 15% of 2N4R tau. M: protein marker, 1: pure 2N4R tau after precipitation purification, 2: western blot with CF633 labeled tau13.
B: CD spectrum of 2N4R tau monomer and filament.
C: ThT assay of 2N4R tau (10 μM), aggregation was induced with 2.5 μM heparin. Data shown are the mean ± SD from three independent measurements (
n = 3).
(TIF)
GUID: 3F4A50B0-7B31-474A-B479-C80F88AAA438
S3 Fig: Comparison of 2N4R tau and heparin CD spectrum.
A: CD spectrum of 2N4R tau monomer and filament.
B: CD spectrum of 2.5 μM and 25 μM heparin.
(TIF)
GUID: E4E8A927-C1E2-4CF5-850F-8D9098A5D9B3
S4 Fig: SDS PAGE of alpha-synuclein and TDP-43 purification. M: Protein marker; 1: Supernatant after affinity chromatography; 2: Elution steps after size exclusion chromatography.
A: SDS PAGE of alpha-synuclein purification.
B: SDS PAGE of TDP-43 purification.
(TIF)
GUID: 9C4BD9E4-57F0-4D07-A55E-E421367C6C75
S5 Fig: Effect of SARS-CoV-2 3CL
pro and tau doses on 2N4R tau aggregation. The endpoint of the relative fluorescence during a ThT assay is shown.
A: Effect of different 3CLpro concentration (0, 0.5, 1, 2.5, 5 and 10 μM) on tau aggregation (Tau concentration was 10 μM).
B: Effect of different tau concentration (0, 5, 10, 20, 40, 60, 80 and 100 μM) on tau aggregation. (3CL
pro concentration was 10 μM). As Control experiments tau at each concentration without protease is shown.
(TIF)
GUID: 7A7437BF-1605-41E0-882C-F3180E9EEBBC
S6 Fig: Negative stain electron microscopy of 3CL
pro induced tau fibrilles.
A-F: Representative micrographs at high (73kx) magnification, showing 3CL
pro induced tau fibrilles.
(TIF)
GUID: 114E2B31-2394-468D-A71B-C5FE8A57F09A
S7 Fig: Effect of 3CL
pro inactivation on tau metabolisation. The protease was inactivated by 10 μM DSF.
A: Analytical HPLC analysis of 2N4R tau incubated with inactivated SARS-CoV-2 3CL
pro for 0, 24, 48 and 72h. The corresponding chromatogram regions of the tau monomer and related metabolites generated by active 3CL
pro are highlighted (I-III).
B: Stability of 2N4R tau monomer after treatment with inactivated 3CL
pro over 72h. The tau monomer amount remains at 95%, compared with a control were tau was treated with active 3CL
pro. In the control experiment the tau monomer amount reduce to around 40%.
C: Chromatogram of peak I (Tau) shown enlarged,
D: Chromatogram of peak region II shown and
E: Chromatogram of peak region III shown enlarged. Data shown are the mean ± SD from three independent measurements (
n = 3).
(TIF)
GUID: 5966FF7F-3890-4924-9584-8D0441E1751E
S8 Fig: Mass spectrometry analysis of tau metabolites (
GDTPSLEDEAAGHVTQAR). Example of a MS spectrum corresponding to a tryptic peptide derived from 2N4R tau (
GDTPSLEDEAAGHVTQAR), b- and y-ions are labelled.
(TIF)
GUID: 096EE5FA-E908-4044-863D-32963A8AB178
S9 Fig: Mass spectrometry analysis of tau metabolites (
SPQLATLADEVSASLAK). Example of a MS spectrum corresponding to a tryptic peptide derived from 2N4R tau (
SPQLATLADEVSASLAK), b- and y-ions are labelled.
(TIF)
GUID: BA269867-4946-4C12-A7BC-B2962BA64941
S10 Fig: Preferred cleavage sequence pattern of SARS-CoV-2 3CL
pro and possible cleavage sites in the tau sequence. 3CL
pro substrate binding site and preferred amino acids are shown and sequence homology of possible cleavage sites. The identical amino acid pattern was checked in the Merops database, if there exist identities to known viral protease cleavage sequences. The following virus proteases were identified: C49.001 (Strawberry mottle virus 3C-like peptidase); C30.001 (Coronavirus picornain 3C-like peptidase-1); C30.003 (Human coronavirus 229E main peptidase); C30.005 (SARS coronavirus picornain 3C-like peptidase) and C30.007 (Coronavirus COVID-19 3C-like peptidase).
(TIF)
GUID: A9132FD7-FDB1-4765-BE95-E66C10C05C7D
S1 Table: Tryptic peptides of 2N4R tau. (PDF)
GUID: BA9C973F-E0FC-4C2F-B1FE-2DA9CD871388
S2 Table: Tryptic peptides of 2N4R tau detected in peak I. (PDF)
GUID: 1E548650-F173-41A2-A35B-F9FF1F6910EE
S3 Table: Tryptic peptides of 2N4R tau detected in peak region II. (PDF)
GUID: 81EB4176-8FC9-401A-BF37-B687FA51EB07
S4 Table: Tryptic peptides of 2N4R tau detected in peak region III. (PDF)
GUID: E666723D-9910-4DEC-8ED6-8552CE9BA998
Data Availability StatementAll relevant data are within the paper and its Supporting information files.
AbstractThe primary function of virus proteases is the proteolytic processing of the viral polyprotein. These enzymes can also cleave host cell proteins, which is important for viral pathogenicity, modulation of cellular processes, viral replication, the defeat of antiviral responses and modulation of the immune response. It is known that COVID-19 can influence multiple tissues or organs and that infection can damage the functionality of the brain in multiple ways. After COVID-19 infections, amyloid-β, neurogranin, tau and phosphorylated tau were detected extracellularly, implicating possible neurodegenerative processes. The present study describes the possible induction of tau aggregation by the SARS-CoV-2 3CL protease (3CLpro) possibly relevant in neuropathology. Further investigations demonstrated that tau was proteolytically cleaved by the viral protease 3CL and, consequently, generated aggregates. However, more evidence is needed to confirm that COVID-19 is able to trigger neurodegenerative diseases.
IntroductionViral pathogens encode their protease(s) or use host proteases for their replication cycle. In the case of acute respiratory syndrome coronavirus 2 (SARS-CoV-2), proteolytic cleavage of the two virus polyproteins generates the various viral proteins needed to form a replication complex required for transcription and replication of the viral genome and subgenomic mRNAs. The key viral enzymes responsible are the papain-like (PLP, nsp3) and 3-chymotrypsin-like proteases (3CLpro) [1''3]. In addition, host cell protein cleavage is a critical component of viral pathogenicity [4], including diverting cellular processes to viral replication, defeating antiviral responses and immune response modulation. Many large-scale analyses of the SARS-CoV-2 infected-cell transcriptome, proteome, phosphoproteome and interactomes are described [5''7]. Regarding the 3CLpro human substrate repertoire, also known as the degradome [8], Pablos et al., 2021 identified over 100 substrates and 58 additional high confidence candidate substrates out of SARS-CoV-2 infected human lung and kidney cells [9].
SARS-CoV-2 was identified in December 2019 as the causative agent of coronavirus disease-19 (COVID-19) first occurring in Wuhan, Hubei province, China [10]. According to the data that were reported to the World Health Organization (WHO) up to the 3rd of January 2023, the global SARS-CoV-2 pandemic was associated with >655 million confirmed cases of infections and >6.6 million virus-related deaths worldwide [11].
It is well known that SARS-CoV-2 infection can influence multiple tissues or organs [12''16]. Post-COVID syndrome (also known as Long-COVID) has also been described as a syndrome that encompasses a prolonged course of various physical and neuropsychiatric symptoms that persist for more than 12 weeks [17, 18]. It has also been reported that COVID-19 can damage the brain in different ways ( Table 1 ).
Table 1Some neurological symptoms caused by COVID-19.
Neurological symptomReferenceLoss of smell (anosmia) and altered taste (ageusia)[19]Myoclonus, cerebellar ataxia, seizure and tremor[20, 21]Headache[22]Cardiorespiratory failure[23]Encephalopathy[24]Acute Disseminated Encephalomyelitis[25]Stroke[26]Guillain-Barre syndrome[27]Douaud et al. 2022 described the dramatic effects of SARS-CoV-2 infections on the brain structure, including a reduction in grey matter thickness, tissue damage in regions that are functionally connected to the primary olfactory cortex and a significant reduction in global brain size [28]. However, so far, there exists no direct link with the generation of neurodegenerative diseases like Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Huntington's disease (HD), spinocerebellar ataxias, corticobasal degeneration, progressive supranuclear palsy, chronic traumatic encephalopathy, or multiple system atrophy. These diseases have many common features, including their chronic and progressive nature, the increased prevalence with age, destruction of neurons in specific areas of the brain, damage to the network of synaptic connections, and selective brain mass loss [29]. Another event is the progressive accumulation of misfolded protein aggregates with well-ordered structures. The proteins most commonly implicated in the accumulation of cerebral misfolded aggregates include amyloid-beta (Aβ), tau, alpha-synuclein (α-Syn) and TAR DNA-binding protein 43 (TDP-43) [29].
After COVID-19 infections in the brain, amyloid-β, neurogranin, tau and phosphorylated tau can be detected extracellularly, implicating possible neurodegenerative processes [30]. Another study demonstrated that the spike protein receptor binding domain binds to heparin and heparin-binding proteins, including amyloid-β, α-synuclein, tau, prion and TDP-43, which may initiate the pathological aggregation of these proteins resulting in neurodegeneration [31, 32]. Ramani et al. 2020 showed that SARS-CoV-2 targets neurons of 3D human brain organoids and neurons invaded with SARS-CoV-2 at the cortical area display altered tau, tau hyperphosphorylation distribution and apparent neuronal death [33].
Tau phosphorylation and tau proteolysis are likely key factors in disease-associated tau aggregation and accumulation. Tau proteolysis can destabilise its primary structure, preventing correct folding and can lead to the formation of aggregated tau species due to a disordered quaternary structure. Tau can be cleaved by various proteolytic enzymes, including caspases, calpains, thrombin, cathepsins, metalloprotease 10, asparagine endopeptidase and puromycin-sensitive aminopeptidase [34].
Here, we report the cleavage and aggregation of tau after SARS-CoV-2 3CLpro treatment in vitro using a combination of ThT assays, negative staining TEM, analytical HPLC and mass spectrometry.
Material and methodsPreparation of alpha-synuclein, TDP-43 and 2N4R tauAlpha-synuclein was cloned, expressed and purified, as described previously [35]. TDP-43 sample was kindly provided by Dr Jeanine Kutzsche (IBI-7, Forschungszentrum J¼lich). The gene for human tau (2N4R isoform, uniprot ID: P10636-8) encodes a protein of 441 amino acids. The respective gene was commercially synthesised and cloned into the pET28A(+) vector (Genentech, San Francisco, USA), without His-tag. Protein expression was performed as described previously [36].
Protein extraction began by dissolving the cell pellet of 1 L expression in 30 ml buffer 1 (50 mM HEPES pH 7.5, 500 mM KCL, 5 mM β-ME and 1 mM EDTA). The dissolved cell pellets were heated for 30 min at 85°C followed by 10 min on ice, and samples were sonicated 3 x 40 seconds at a power setting of 5 in an ultrasonic cell disruptor Modell 250 (Branson Ultrasonic, Brookfield, USA). Bacterial debris was pelleted for 50 min at 10,000 x g. Soluble tau protein was precipitated from the supernatant by adding 40 ml of a saturated ammonium sulfate solution and incubated for 30 minutes at room temperature. Afterwards, the samples were centrifuged for 30 min at 10,000 x g, and the pellet was resuspended in buffer 2 (50 mM HEPES pH 7.5, 50 mM KCL, 1.5 M ammonium sulfate, 2 mM TCEP and 1 mM EDTA). The solution was centrifuged for 30 minutes at 10,000 x g, and the pellet was resolved in 10 mL ddH2O and 2 mM TCEP. The sample was centrifuged again for 30 minutes at 10,000 x g, and the appearing pellet was resuspended in buffer 3 (20 mM HEPES pH 6.7, 150 mM NaCl, 2 mM TCEP and 1 mM EDTA). The sample was centrifuged for 1h at 12,000 x g, and the supernatant was dialysed overnight at 6°C against buffer 4 (50 mM ammonium acetate pH 7.4, 1 mM TCEP). The protein purity was assessed by SDS/PAGE (15%).
Western blot analysesFor western blots, a fluorescent anti-tau antibody was used. Therefore tau13 (Biolegend, San Diego, USA) was labelled with CF633 (Biotium, Freemont, USA), and the labelling process was performed as described previously [37]. 2N4R tau recombinant protein samples were prepared in Laemmli buffer (final 1 composition: 20 mM Tris, pH 6.8, 2% SDS, 6% glycerol, 1% β-ME, 0.002% Bromophenol Blue). All samples were heated at 95°C for 5 min and separated using SDS PAGE (15%). Proteins were then transferred to a polyvinylidene fluoride (PVDF) membrane (Thermo Fisher Scientific, Waltham, USA) at 500 mA for 40 min. After a washing step for 15 min in Tris-buffered saline tween buffer (TBS-T) (20 mM Tris, 150 mM NaCl, 0.1% Tween 20), the membrane was blocked for 1 h with 2.5% milk powder/TBS-T. Next, the membrane was washed with TBS-T, 2 5 min and in the last step for 15 min. Tau13 stocks were 1 mg/ml and were diluted in TBS-T (1:5000). The membrane was incubated with the antibody for 1.5 h. at RT. After a final wash step (2 5 min and 1 10 min), TBS-T was performed. Detection based on the CF633 fluorescence of the labelled tau13 antibody. Bio-Rad universal hood II and Chemidoc XRS camera and Quantity One 4.6.5 software enabled the visualisation and quantification of the protein bands.
Thioflavin T aggregation (ThT) assayThT aggregation assays were conducted in Corning half area 96-well plates with the non-binding surface (Corning No. 3881, Glendale, AZ, USA). As a control, polymerisation of 2N4R tau was initiated in the presence of the aggregation inducer heparin (Sigma-Aldrich, USA) with a molar ratio of 4:1 (Tau:heparin). 10 μM tau was incubated with 2.5 μM heparin (the final volume of the reaction mixture was 150 μl). The experiment buffer contained 20 mM Tris pH 7.2, 200 mM NaCl, 1 mM TCEP and 10 μM ThT. Fluorescence intensities were measured at 6 minutes intervals over 30 hours at 350 rpm and 37°C using an Infinite 200 PRO plate reader (Tecan, M¤nnedorf, Switzerland). The excitation and emission wavelengths were 440 and 490 nm, respectively. All measurements were performed in triplicate, and data are presented as mean ± SD.
ThT assay using SARS-CoV-2 3CLpro as tau aggregation inducerThT assays were performed as described before. Instead of heparin, 10 μM SARS-CoV-2 3CLpro was used as an aggregation inducer. In a preliminary test, the effect of 3CLpro against 10 μM 2N4R tau, α synuclein and TDP-43 was tested over 24h. As a control, the same experiment was performed with the single proteins.
A further experiment was performed with inactivated 3CLpro, the protease was incubated with an equimolar concentration of Disulfiram (DSF) (10μM) for 30 minutes at RT, after 10 μM 2N4R tau and ThT was added, and the experiment was running for 24h. As a control, 2N4R tau was incubated with DSF and monitored for the same experimental time.
Furthermore, a ThT assay of 10 μM tau and 3CLpro were stopped after 24h, and the protease was inactivated through DSF addition (10 μM) and incubated for 30 minutes at RT. Afterwards, a new tau sample (10μM) was added. The same procedure without inactivating the protease was followed as a control. All measurements were performed in triplicate, and data are presented as mean ± SD.
Circular dichroism (CD) spectroscopyCD measurements were carried out with a Jasco J-1100 Spectropolarimeter (Jasco, Germany). Far-UV spectra were measured in 190 to 250 nm using a 2N4R tau (monomer and filament) concentration of 10 μM in 20 mM K2HPO4/KH2PO4 pH 7.0.
2N4R tau aggregates were generated in the presence of heparin (Sigma-Aldrich, USA) with a molar ratio of 4:1 (Tau:heparin). 10 μM tau was incubated with 2.5 μM heparin. 2.5 μM heparin was measured as blank sample and the signal was subtracted from the tau signal. As an additional control the CD spectrum of 25 μM heparin was collected.
A 1 mm path length cell was used for the measurements; 10 repeat scans were obtained for each sample, and five scans were conducted to establish the respective baselines. The averaged baseline spectrum was subtracted from the averaged sample spectrum. The results are presented as molar ellipticity [θ], according to the Eq (1):
where θ is the ellipticity measured at the wavelength Î>> (deg), c is the protein concentration (mol/L), 0.001 is the cell path length (cm), and n is the number of amino acids.
Investigation of tau and 3CLpro doses dependency on the aggregation processDifferent concentrations were titrated to investigate tau, and 3CLpro doses dependency on the 2N4R tau fibril formation and a ThT assay was performed as described before. The effect of 0, 2.5, 5, 10, 25 and 50 μM 3CLpro was tested against 10 μM tau over 24h. We also tested the opposite effect, where 0, 5, 10, 20, 40, 60, 80, and 100 μM of tau were tested against 10 μM 3CLpro. All experiments were performed in triplicate, and data are presented as mean ± SD.
Stability of tau in the presence of Sars-CoV-2 3CLpro investigated by High-performance liquid chromatography (HPLC)To explore the proteolytic degradation of tau by 3CLpro samples after 0, 24, 48 and 72 h incubation were analysed by high-performance liquid chromatography (HPLC). After incubation the samples were centrifuged for 60 minutes at 10,000 x g, to separate aggregated and soluble tau fragments.
Agilent 1260 Infinity II system (Agilent Technologies, Santa Clara, CA, USA), equipped with a quaternary pump, autosampler, heated column compartment, multi-wavelength detector (MWD) and an analytical fraction collector, was used. 20 μL of sample solution was injected into an Agilent Zorbax 300-SB C8 4.6*250 mm, 5 μm reversed-phase liquid chromatography column (Agilent Technologies, Santa Clara, CA, USA), which was heated to 80°C. Mobile phases consisted of A: Water + 0.1% Trifluoroacetic acid (TFA) and B: Acetonitrile + 0.1% TFA. Analyte elution was accomplished by a linear gradient from 10% to 80% buffer B in 20 min. Chromatograms were acquired at 214 nm and 280 nm. Furthermore, data acquisition and evaluation were performed with the Agilent OpenLab software (Version 2.6). The mean peak area of each triplicate was plotted against incubation time. Chromatograms of tau with 3CLpro and chromatograms with a single protein were investigated for metabolite formation after an incubation period of up to 72 h. The peaks related to the sample in which both proteins were present (max incubation 72 h) were considered potential metabolites of the tau protein produced by Sars-CoV-2 3CLpro.
Purification of tau metabolites after proteolytic degradation by Sars-CoV-2 3CLproTo further investigate tau metabolites produced by incubation with Sars-CoV-2 3CLpro, we used HPLC and further mass spectrometry (MS) analysis. Tau was incubated with the protease for 72h at 37°C and 500 rpm. HPLC conditions were the same as described above. 100 μL of the sample was applied to the column per each chromatography run, and fractions were collected every minute. Fractions containing the same peak were pooled and lyophilised; subsequently, the samples were submitted for MS analysis.
Sample processing and mass spectrometryLyophilised samples were resuspended in 500 μL 0.1% trifluoroacetic acid (TFA) and digested with trypsin (Serva, Heidelberg, Germany) in 50 mM NH4HCO3 overnight at 37°C. Tryptic peptides were extracted with 0.1% TFA and subjected to MS-coupled liquid chromatography. Briefly, for peptide separation over a 55-minute LC-gradient with 300 nL/min in an Ultimate 3000 Rapid Separation liquid chromatography system (Thermo Scientific, Bremen, Germany) equipped with an Acclaim PepMap 100 C18 column (75 μm inner diameter, 25 cm length, 2 mm particle size from Thermo Scientific, Bremen, Germany) was used. MS analysis was carried out on a Q-Exactive plus mass spectrometer (Thermo Scientific, Bremen, Germany) operating in positive mode and equipped with a nanoelectrospray ionisation source. The capillary temperature was set to 250°C and the source voltage to 1.5 kV. Survey scans were carried out over a mass range from 200''2,000 m/z at a resolution of 70,000 (at 200 m/z). The target value for the automatic gain control was 3,000,000, and the maximum fills time was 50 ms. The 20 most intense peptide ions (excluding singly charged ions) were selected for fragmentation. Peptide fragments were analysed using a maximal fill time of 50 ms, automatic gain control target value of 100,000 and a resolution of 17,500 (at 200 m/z). Already fragmented ions were excluded for fragmentation for 10 seconds.
Acquired spectra were searched using Sequest HT within Proteome Discoverer version 2.4.1.15 against the SwissProt Homo sapiens proteome dataset (UP000005640, 75777 sequences) with the inserted sequence of the human tau protein and an E.coli BL21 (DE3) database (UP000002032, 4156 sequences). Methionine oxidation was considered a variable modification and tryptic cleavage specificity with a maximum of two missed cleavage sites. For the main search, a precursor mass tolerance of 10 ppm and a mass tolerance of 0.02 Da were applied for fragment spectra. For the semi-specific tryptic search of peptides, PEAKS Studio 10.6 Build 220201221 was used, and the above human database was searched with an error tolerance of 20 ppm for parent masses and an error tolerance of 0.2 Da for fragment masses.
Surface-based fluorescence intensity distribution analysisTo quantify tau aggregation due to 3CLpro activity, surface-based fluorescence intensity distribution analysis (sFIDA) was performed according to the biochemical principle of Kravchenko et al. 2017, and Herrmann et al. 2017 [39, 40]. Therefore, we used 384-Well plates (Greiner, Kremsm¼nster, Austria) to incubate the capture-antibody tau12 in 0.1 M carbonate at a 2.5 μg/ml concentration. After a fivefold washing step with TBS-T and TBS, 80 μl of blocking solution (Candor Bioscience, Wangen, Germany) was added and incubated for 1.5 h. Afterwards, the plate was washed like previously described, and 20 μl of tau conjugated silica-nanoparticles (SiNaPs) and tau aggregates diluted in low cross buffer strong (Candor Bioscience GmbH, Wangen in Allg¤u, Germany) were added. In Addition, 20 μl of 10 nM and 100 nM tau monomer were applied.
To investigate the formation of tau oligomers or aggregates induced by 3CLpro, 5 μM tau monomer was incubated with 5 μM 3CLpro for 72 h. The negative control was established equivalently; however, the protease was previously inactivated with 10 μM Disulfiram (DSF).
The samples, buffer control (BC) and capture control (CC), were incubated for 2 h and washed five times with TBS. For capture control, the capture antibody was omitted. As a detection probe, 20 μl of 0.078 μg/ml tau13 CF633 in TBS was used. After 1 h of incubation, the wells were washed five times with TBS, and the buffer was changed against TBS-ProClin. The SiNaPs and antibodies used were synthesised and labelled according to the previously described principle [37, 41].
Negative staining transmission electron microscopy (TEM)Tau samples were prepared as follows, 20 μM tau and 10 μM 3CLpro were incubated for 72 h at 37°C. To prepare specimens for negative staining TEM, a total volume of 3 μL from the corresponding sample was pipetted onto carbon coated 300 Mesh copper EM grids, which were operated by anti-capillary tweezers and glow discharged in advance for 90 seconds using a PELCO easiGlow' (Ted Pella, Inc., Redding, California, USA) at 0.39 mbar and 15 mA. After an incubation time of 1 min excess liquid was blotted away by touching the edge of the grid with filter paper. Subsequently the grids were stained with two 4 μL droplets of a 2% Uranyl acetate solution. While the first droplet's excess liquid was immediately blotted after application, the second droplet stayed on the grid for an incubation time of 1 min before blotting. Finally, the grids were left to dry at room temperature for approximately 1 min. These negatively stained samples were examined on a Talos L120C G2 transmission electron microscope (Thermo Fisher Scientific, Waltham, Massachusetts, USA) which was operated at 120 kV (LaB6 (Lanthanum hexaboride)/Denka). Micrographs were collected in medium magnification (6700x) and high magnification (73kx) on a 4k x 4k Ceta 16M CEMOS camera using the Velox' software (Thermo Fisher Scientific, Waltham, Massachusetts, USA).
Results and discussionPurification of 2N4R tau with a precipitation approach and characterisation of the protein2N4R tau was expressed in BL21 (DE3) (T1) E. coli and purified by a precipitation approach. 2N4R tau consists of 441 amino acids with an approximated molecular weight of 46 kDa. The purity was assessed by SDS PAGE (S1 Fig). However, the protein presented a single band on a denaturing SDS-PAGE gel with an apparent molecular mass of around 67 kDa, this behavior was described previously [42, 43]. A western blot with the specific antibody (Tau13, Biolegend) confirmed the target protein (S2A Fig). Following successful purification, 2N4R tau was characterised to compare the properties to those previously reported [44''47]. It is well known that tau, in the monomeric state, is inherently unfolded, with predominantly random-coil conformation. Our CD analysis confirmed this observation for the purified protein, with minimum peaks around 200 nm (S2B Fig). Tau aggregation was investigated using ThT assay and heparin as an inducer [48]. The results of the ThT assay indicated that heparin promoted the induction and acceleration of tau aggregation within 24h (S2C Fig). The structural changes of tau in the presence of heparin were followed by CD spectroscopy, demonstrating a shift of the absorbance spectrum from 202 (random-coil conformation) to 213 (beta-sheet conformation) nm (S2B Fig). As a control, the CD spectrum of 2.5 μM heparin was measured, the spectra showed no specific minimum at 213 nm (S3B Fig). At a heparin concentration of 25 μM, the CD spectrum showed a minimum at around 220 nm (S3B Fig). However this heparin concentration was not reached during the experiment. Those results demonstrated that tau had been successfully aggregated by heparin because of the characteristic transition from a random coil to beta-sheet conformation in the tau secondary structure [45].
Identification and characterisation of tau aggregation events induced by SARS-CoV-2 3CLpro using ThT assayTo identify a possible aggregation effect caused by SARS-CoV-2 3CLpro on tau, alpha-synuclein and TDP-43 proteins, a ThT fibrillation assay was performed. The purity of alpha-synuclein and TDP-43 was assessed by SDS PAGE (S4 Fig). The preliminary test showed that tau aggregates increased over time after the addition of 10 μM of SARS-CoV-2 3CLpro, which was not observed for alpha-synuclein and TDP-43 ( Fig 1A ). To confirm our preliminary results, control experiments using the single proteins was performed, which indicated no signal of aggregation over the time ( Fig 1B ).
Effect of SARS-CoV-2 3CLpro on 2N4R tau aggregation and effect of 3CLpro inactivation on tau aggregation.A: ThT assay of 2N4R tau, α-Synuclein and TDP-43, 3CLpro used as aggregation inducer. The experiment was performed for 24 h, 37°C and 600 rpm. B: Control ThT assay of single 3CLpro, α-Synuclein, TDP-43 and tau. C: ThT assay of inactivated 3CLpro, tau aggregation was not observed. D: ThT assay of 2N4R tau, aggregation was induced by 3CLpro. After 24h DSF inactivated the protease and after 30 minutes of incubation, 10 μM fresh tau was added. Data shown are the mean ± SD from three independent measurements (n = 3).
Additional ThT experiments were performed to evaluate the dose dependency of SARS-CoV-2 3CLpro and 2N4R tau concentration on the aggregation behaviour of tau. A higher concentration of the protease (0, 0.5, 1, 2.5, 5 and 10 μM) caused a higher amount of the tau aggregates in a given time of 24h (S5A Fig). Similarly, the titration of tau at different concentrations (0, 5, 10, 20, 40, 60, 80 and 100 μM) resulted in a dose-dependent manner to a higher amount of aggregates (S5B Fig).
To extend our analysis of the tau aggregation process induced by 3CLpro, negative staining transmission electron microscopy (TEM) was performed on solutions containing tau aggregates after treatment with the protease. The analysis demonstrated that the solutions contain amorphous aggregates and fibrils ( Fig 2A and 2B and S6 Fig). The tau fibrils morphology is similar to those described in previous studies [44''47].
Negative stain TEM of 3CLpro induced tau fibrils.A: Representative micrograph at medium (6700x) magnification. B: Representative micrographs at high (73kx) magnification. Asterisks label vesicle structures.
Besides the tau fibrils, micelle or vesicle-like structures were observed ( Fig 2B ). As described before, anionic micelles or vesicles can serve to nucleate tau fibrillation [49, 50], which may explain the observation of the vesicle-like structures in the negative stain TEM micrographs.
Effect of SARS-CoV-2 3CLpro inactivation on tau aggregationThere exist two possibilities for how SARS-CoV-2 3CLpro induced tau aggregation: (1) both proteins interact and form aggregates; (2) the protease cleaves tau and thus produces insoluble fragments that will initiate the aggregation process. To discover the possible forms of the aggregation endured by tau protein, we performed ThT assays using inactivated 3CLpro by disulfiram (DSF), a known 3CLpro inhibitor [51]. The results demonstrated that inactivation of the protease prevents tau aggregation ( Fig 1C ), which allows us to suggest that the proteolysis role of the 3CLpro initiates the aggregation process. The addition of DSF in a running ThT assay stopped the tau aggregation immediately ( Fig 1D ).
Stability of tau under SARS-CoV-2 3CLpro influenceThe stability of 2N4R tau under the influence of SARS-CoV-2 3CLpro was investigated using analytical HPLC experiments. Interestingly, the results demonstrated an evident cleavage of tau protein by the virus protease ( Fig 3 ). As described before, the protein mix was analysed over 0, 24, 48 and 72 h of incubation. The corresponding tau monomer peak (I) (retention time: 10.6 minutes) in the chromatogram decreased over 72h ( Fig 3A ), which can also be observed in a silver-stained SDS PAGE ( Fig 3C ). Beside the reduction of the monomer form of tau the presence of a new protein band around 25 kDa was observed, which allow us to suggest that it represents the tau fragments after the 3CLpro proteolytic effect. Additionally, two additional peaks were observed on the analytical HPLC chromatogram (II, III) ( Fig 3A, 3D and 3E ). SDS PAGE analysis of the related fractions (regions II and III) also validated the increasing protein bands over experimental time.
Effect of SARS-CoV-2 3CLpro on 2N4R tau degradation.A: Analytical HPLC analysis of 2N4R tau incubated with SARS-CoV-2 3CLpro for 0, 24, 48 and 72h. The corresponding chromatogram regions of the tau monomer and related metabolites are labelled (I-III). B: Stability of 2N4R tau monomer after treatment with 3CLpro over 72h. Single tau and 3CLpro are shown as control. After 3CLpro treatment, the tau monomer amount decreases by about 60%. C: Chromatogram of peak I (Tau) shown enlarged, a silver stained SDS PAGE demonstrated that the 2N4R tau amount decreased over 72h treatment with 3CLpro and a protein band increases at 25 kDa. D: Chromatogram of peak region II shows enlarged three protein bands appearing over 72h experimental time. E: Chromatogram of peak region III shown enlarged, two protein bands appear over the 72h experimental time.
Based on our results, we assumed that SARS-CoV-2 3CLpro cleaves tau possibly in different sites, resulting in truncated tau species. After 72 h experimental time, the 2N4R tau amount was reduced by about 60% related to the start point. Interestingly, in the first 24 h, the degradation process declines substantially to about 50% of the monomer amount; however, during the remaining 48 h, the monomer amount reduced by just around 10% ( Fig 3B ). This observation can be attributed to the diminished amount of the monomer itself.
Analytical HPLC with 2N4R tau and inactivated 3CLpro demonstrated that after 72 h, tau is slightly degradated (~5%) (S7 Fig).
Identification of tau fragments using mass spectrometryWe have used mass spectrometry (MS) experiments to confirm tau fragments in the HPLC peaks I, II and III. Untreated 2N4R tau was used as control; in all tested samples, tau could be detected ( Fig 4 ). The determination of tryptic tau peptides AEPRQEFEVMEDHAGTYGGLGDR, GDTPSLEDEAAGHVTQAR and SPQLATLADEVSASLAK are shown in Fig 4A (S8 and S9 Figs). All identified tryptic tau peptides are listed in S1''S4 Tables (Tryptic peptides that occurred less than three times are not shown).
Mass spectrometry analysis of tau metabolites.A: Example of an MS spectrum corresponding to a tryptic peptide derived from 2N4R tau (AEPRQEFEVMEDHAGTYGGLGDR), b- and y-ions are labelled. B: 2N4R tau sequences and tryptic peptides, which could be identified in the corresponding samples, are highlighted. Asterisks label tryptic 2N4R tau peptides, which could not be identified in the three peak samples.
In the tau control, 111 tryptic peptides could be determined, and AEPRQEFEVMEDHAGTYGGLGDR had the highest appearance (eight times). Interestingly, we could not identify, in fractions II and III, the N-terminal tryptic peptides detected in the control and peak I (AEPRQEFEVMEDHAGTYGGLGDR and AGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQ) ( Fig 4B ). Additionally, tryptic peptides in the mid-region and C-terminus of the control sequence could not be detected in fractions related to peak I, II and III (TPPSSGEPPKSGDRSGYSSPGSPGTPGSR, QTAPVPMPDLK and TDHGAEIVYKSPVVSGD). Likewise, in the control sample, the peptide (GSLGNIHHKPGGGQVEVK) was not detected (peak I) ( Fig 4B ).
Under the experimental conditions (Tau degradation by 3CLpro), no fragments are generated that, after tryptic digestion, are amenable of identification, which may influence the composition and number of tryptic tau peptides in the four tested samples, as shown in Table 2 .
Table 2The number of tryptic tau peptides in control and the tested HPLC samples.
SampleNumber tryptic peptidesPeptides with the highest appearance2N4R tau111AEPRQEFEVMEDHAGTYGGLGDR (8x)I66SPQLATLADEVSASLAK (8x)II46GDTPSLEDEAAGHVTQAR (6x)II63SPQLATLADEVSASLAK (15x)2N4R tau contains a sequence 241SRLQTAPV248 (QTAPVPMPDLK tryptic peptide absent in peak I) which shows similarities to the preferred 3CLpro cleavage pattern (S10 Fig). A tau cleavage at this site could generate two fragments with sizes of 25 and 20 kDa, shown on the SDS page for peak I ( Fig 3C and 3E ). Furthermore, at the N-terminus of tau, there are several potential cleavage sites for 3CLpro, which can generate fragments with molecular weights between 45 and 27 kDa. Possible 3CLpro cleavage sites relating to the tau protein sequence are shown in S10 Fig; this analysis is based on the amino acid preference in the SARS-CoV-2 3CLpro substrate binding site (Information conceived from the Merops database) [52] and similar amino acid sequences in the tau sequence. Four sequences showed similarities with the 3C-like protease from coronavirus-2 and one with a 3C-like peptidase from strawberry mottle virus (S10 Fig).
The results described in this study indicated that 2N4R tau is proteolytically cleaved by 3CLpro, and the cleavage is related to tau aggregation events. It has previously been described that tau proteolysis is associated with aggregation and that the tau protein has cleavage sites for different proteolytic enzymes [34] ( Table 3 ).
Table 3Examples of proteases with proteolytic activity against tau.
ProteaseCleavage siteReferenceCaspase-6D13-H14[53]Caspase-3D25-Q26; K44-E45[54]Calpain-1 and -2R230-T231[55, 56]Caspase-2D314-L315[57]Calpain-1K44-E45, R242-L243[58, 59]ADAM10A152-T153[60]ThrombinR155-G156; R209-S210[61]ChymotrypsinY197-S198[62]Asparagine endopeptidaseN255-V256; N368-K369[63]Caspase-1, -3, -6, -7 and -8D421-S422[64]Tau Cleavage sites of Caspase-3 (D25-Q26) and Calpain-1 (R242-L243) are located near possible 3CLpro cleavage sites of tau (Q26-G27 and Q244-T245) (S10 Fig).
Surface-based fluorescence intensity distribution analysisSurface-based fluorescence intensity distribution analysis (sFIDA) was performed to quantify the tau oligomers and aggregates after treatment with 3CLpro. The technique employs a similar biochemical setup as ELISA-like techniques. However, sFIDA uses the same epitope to capture and detect antibodies and features single-particle sensitivity through a microscopy-based readout (Herrmann et al., 2017). Recently, sFIDA was applied to quantify tau aggregates in cerebrospinal fluid (CSF) and demonstrated its applicability in clinical settings [37]. Initial sFIDA experiments include analysis of tau monomers, tau aggregates and tau SiNaPs ( Fig 5A''5C ). To quantify tau aggregates formed by 3CLpro proteolysis, two approaches were tested: tau plus active 3CLpro and tau plus inactivated 3CLpro (with the addition of disulfiram). As shown in Fig 5D , tau samples containing active 3CLpro yielded a similar aggregate-specific readout compared with tau samples in the presence of inactivated protease. Compared to the tau aggregate control, however, only a small fraction of the employed tau substrate was converted into aggregates.
sFIDA experiments.Samples, buffer control (BC) and capture control (CC) were tested. Pixel counts per concentration are shown for A: Tau monomer control, B: Tau aggregate control, C: Tau SiNaPs and D: Influence of active 3CLpro on tau aggregation.
It is well known that the structural diversity of tau aggregates can make their detection technically challenging [65].
For the sFIDA experiments anti-tau12 and anti-tau13 (Biolegend) were used, and both antibodies interact with the N-terminal region of tau (Tau 6''18 and 15''25) [66]. According to the mass spec results described before, tau epitope regions for anti-tau12 and anti-tau13 are cleaved and therefore cannot react with the respective antibodies in the sFIDA assays. Additionally, remaining epitopes might be masked by aggregate core formation and can therefore not any more detected by the employed antibody system.
Conclusion and future workThe proportion of older adults in the population is increasing in almost all countries. Worldwide, around 55 million people have dementia, which is expected to increase to 78 million in 2030 and 139 million in 2050 [67]. Different dementias show a conformationally altered tau, the protein detaches from microtubules and aggregates into oligomers and neurofibrillary tangles, which can be secreted from neurons, and spread through the brain during disease progression.
The COVID-19 pandemic has increasingly moved virus infections into the scientific spotlight and has shown that this infection can damage the brain in many ways. The molecular underpinnings of neurodegenerative processes need to be investigated to develop appropriate therapies. Proteolysis of tau protein may be a crucial factor in forming toxic aggregates. Our results demonstrated that the SARS-CoV-2 3CLpro can cleave 2N4R tau into fragments and thus induce protein aggregation in vitro. TEM revealed amorphous aggregates and fibrils; in addition to tau fibrils, structures similar to micelles or vesicles were also observed, serving to nucleate tau fibrillation. However, further experiments such as adjustment and optimisation of sFIDA assay (e.g. antibodies); cleavage and accessibility of tau binding regions for specific antibodies; cell toxicity of tau peptides and related aggregates; in vivo experiments to observe the role of the 3CLpro on tau aggregation are needed, to get a closer assessment of the tau cleavage by SARS-CoV-2 3CLpro and if this process plays a pivotal role in vivo.
Supporting informationS1 FigSDS PAGE of 2N4R tau purification. M: Protein marker; 1: Supernatant after cell disruption; 2: Supernatant after ammonium sulfate precipitation; 3: Pellet after ammonium sulfate precipitation solved in buffer 2; 4: SN after centrifugation pellet solved in buffer 2; 5: Pellet solved in ddH2O and 2 mM TCEP; 6: Pellet was solved in buffer 3; 7: SN after centrifugation pellet solved in buffer 3; 8: Sample after dialysis against buffer 4.
(TIF)
S2 FigCharacterization of 2N4R tau.A: SDS PAGE 15% of 2N4R tau. M: protein marker, 1: pure 2N4R tau after precipitation purification, 2: western blot with CF633 labeled tau13. B: CD spectrum of 2N4R tau monomer and filament. C: ThT assay of 2N4R tau (10 μM), aggregation was induced with 2.5 μM heparin. Data shown are the mean ± SD from three independent measurements (n = 3).
(TIF)
S3 FigComparison of 2N4R tau and heparin CD spectrum.A: CD spectrum of 2N4R tau monomer and filament. B: CD spectrum of 2.5 μM and 25 μM heparin.
(TIF)
S4 FigSDS PAGE of alpha-synuclein and TDP-43 purification. M: Protein marker; 1: Supernatant after affinity chromatography; 2: Elution steps after size exclusion chromatography. A: SDS PAGE of alpha-synuclein purification. B: SDS PAGE of TDP-43 purification.
(TIF)
S5 FigEffect of SARS-CoV-2 3CLpro and tau doses on 2N4R tau aggregation. The endpoint of the relative fluorescence during a ThT assay is shown. A: Effect of different 3CLpro concentration (0, 0.5, 1, 2.5, 5 and 10 μM) on tau aggregation (Tau concentration was 10 μM). B: Effect of different tau concentration (0, 5, 10, 20, 40, 60, 80 and 100 μM) on tau aggregation. (3CLpro concentration was 10 μM). As Control experiments tau at each concentration without protease is shown.
(TIF)
S6 FigNegative stain electron microscopy of 3CLpro induced tau fibrilles.A-F: Representative micrographs at high (73kx) magnification, showing 3CLpro induced tau fibrilles.
(TIF)
S7 FigEffect of 3CLpro inactivation on tau metabolisation. The protease was inactivated by 10 μM DSF. A: Analytical HPLC analysis of 2N4R tau incubated with inactivated SARS-CoV-2 3CLpro for 0, 24, 48 and 72h. The corresponding chromatogram regions of the tau monomer and related metabolites generated by active 3CLpro are highlighted (I-III). B: Stability of 2N4R tau monomer after treatment with inactivated 3CLpro over 72h. The tau monomer amount remains at 95%, compared with a control were tau was treated with active 3CLpro. In the control experiment the tau monomer amount reduce to around 40%. C: Chromatogram of peak I (Tau) shown enlarged, D: Chromatogram of peak region II shown and E: Chromatogram of peak region III shown enlarged. Data shown are the mean ± SD from three independent measurements (n = 3).
(TIF)
S8 FigMass spectrometry analysis of tau metabolites (GDTPSLEDEAAGHVTQAR). Example of a MS spectrum corresponding to a tryptic peptide derived from 2N4R tau (GDTPSLEDEAAGHVTQAR), b- and y-ions are labelled.
(TIF)
S9 FigMass spectrometry analysis of tau metabolites (SPQLATLADEVSASLAK). Example of a MS spectrum corresponding to a tryptic peptide derived from 2N4R tau (SPQLATLADEVSASLAK), b- and y-ions are labelled.
(TIF)
S10 FigPreferred cleavage sequence pattern of SARS-CoV-2 3CLpro and possible cleavage sites in the tau sequence. 3CLpro substrate binding site and preferred amino acids are shown and sequence homology of possible cleavage sites. The identical amino acid pattern was checked in the Merops database, if there exist identities to known viral protease cleavage sequences. The following virus proteases were identified: C49.001 (Strawberry mottle virus 3C-like peptidase); C30.001 (Coronavirus picornain 3C-like peptidase-1); C30.003 (Human coronavirus 229E main peptidase); C30.005 (SARS coronavirus picornain 3C-like peptidase) and C30.007 (Coronavirus COVID-19 3C-like peptidase).
(TIF)
S1 TableTryptic peptides of 2N4R tau. (PDF)
S2 TableTryptic peptides of 2N4R tau detected in peak I. (PDF)
S3 TableTryptic peptides of 2N4R tau detected in peak region II. (PDF)
S4 TableTryptic peptides of 2N4R tau detected in peak region III. (PDF)
AcknowledgmentsThe authors gratefully acknowledge the electron microscopy training, imaging and access time granted by the life science EM facility of the Ernst-Ruska Centre at Forschungszentrum J¼lich. We want to thank the support of the Institute of Biological Information Processing (IBI-7) Forschungszentrum J¼lich, Germany.
Funding StatementD.W. is supported by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project-ID 267205415, SFB 1208. sFIDA was supported by the programs ''Biomarkers Across Neurodegenerative Diseases I + II'' of The Alzheimer's Association, Alzheimer's Research UK and the Weston Brain Institute (11084 and BAND-19-614337). We are also grateful for support from The Michael J. Fox Foundation for Parkinson's Research (14977, 009889), from the ALS Association and from the Packard Center (19-SI-476). We received further funding from the Deutsche Forschungsgemeinschaft (INST 208/616-1 FUGG, INST 208/794-1 FUGG) and the Helmholtz Association (HVF0079).
References2.
Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
. Science . 2020; 368 :1331''1335. doi: 10.1126/science.abb4489 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 3.
Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
. Nature . 2020; 587 :657''662. doi: 10.1038/s41586-020-2601-5 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 4.
Jagdeo JM, Dufour A, Klein T, Solis N, Kleifeld O, Kizhakkedathu J, et al. N-Terminomics TAILS Identifies Host Cell Substrates of Poliovirus and Coxsackievirus B3 3C Proteinases That Modulate Virus Infection
. J Virol . 2018; 92 :e02211''e02217. doi: 10.1128/JVI.02211-17 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 5.
Stukalov A, Girault V, Grass V, Karayel O, Bergant V, Urban C, et al. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV
. Nature . 2021; 594 :246''252. doi: 10.1038/s41586-021-03493-4 [PubMed] [CrossRef] [Google Scholar] 6.
Bouhaddou M, Memon D, Meyer B, White KM, Rezelj VV, Correa Marrero M, et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection
. Cell . 2020; 182 :685''712.e19. doi: 10.1016/j.cell.2020.06.034 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 7.
Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
. Nature . 2020; 583 :459''468. doi: 10.1038/s41586-020-2286-9 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 8.
Lopez-Otın C, Overall CM. Protease degradomics: a new challenge for proteomics
. Nat Rev Mol Cell Biol . 2002; 3 :509''519. doi: 10.1038/nrm858 [PubMed] [CrossRef] [Google Scholar] 9.
Pablos I, Machado Y, de Jesus HCR, Mohamud Y, Kappelhoff R, Lindskog C, et al. Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CLpro substrate degradome
. Cell Rep . 2021; 37 :109892. doi: 10.1016/j.celrep.2021.109892 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 10.
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China
. Nature . 2020; 579 :265''269. doi: 10.1038/s41586-020-2008-3 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 11. WHO. 2023. World Health Organization, Coronavirus disease 2019 (COVID-19) Dashboard, 03.01.2023.
13.
Giannis D, Ziogas I, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past
. J Clin Virol . 2020; 127 :104362. doi: 10.1016/j.jcv.2020.104362 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 14.
Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: Observations and hypotheses
. Lancet . 2020; 395 :1517''1520. doi: 10.1016/S0140-6736(20)30920-X [PMC free article] [PubMed] [CrossRef] [Google Scholar] 15.
Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection
. Gut . 2020; 69 :997''1001. doi: 10.1136/gutjnl-2020-321013 [PubMed] [CrossRef] [Google Scholar] 17.
Mahase E. Covid-19: What do we know about ''long covid''? Brit Med J . 2020; 14 :370. doi: 10.1136/bmj.m2815 [PubMed] [CrossRef] [Google Scholar] 19.
Shelton JF, Shastri AJ, Fletez-Brant K, Aslibekyan S, Auton A. The UGT2A1/UGT2A2 locus is associated with COVID-19-related loss of smell or taste
. Nat Genet . 2022; 54 :121''124. doi: 10.1038/s41588-021-00986-w [PubMed] [CrossRef] [Google Scholar] 20.
Chan JL, Murphy KA, Sarna JR. Myoclonus and cerebellar ataxia associated with COVID-19: a case report and systematic review
. J Neurol . 2021; 268 :3517''3548. doi: 10.1007/s00415-021-10458-0 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 21.
Cartella S, Terranova C, Arena I, Quartarone A, Girlanda P. Impact of Covid-19 on essential tremor and dystonic tremor: Experience of an Italian centre
. J Neurol Sci . 2021; 429 :119437. doi: 10.1016/j.jns.2021.119437 [CrossRef] [Google Scholar] 22.
Kacprzak A, Malczewski D, Domitrz I. Headache Attributed to SARS-CoV-2 Infection or COVID-19 Related Headache'--Not Migraine-like Problem-Original Research
. Brain Sci . 2021; 11 :1406. doi: 10.3390/brainsci11111406 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 23.
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms
. ACS Chem Neurosci . 2020; 11 :995''998. doi: 10.1021/acschemneuro.0c00122 [PubMed] [CrossRef] [Google Scholar] 24.
Uginet M, Breville G, Assal F, L¶vblad KO, Vargas MI, Pugin J, et al. COVID'19 encephalopathy: Clinical and neurobiological features
. J Med Virol . 2021; 93 :4374''4381. doi: 10.1002/jmv.26973 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 25.
Mahapure KS, Prabhune AS, Chouvhan AV. COVID-19-associated acute disseminated encephalomyelitis: A systematic review
. Asian J Neurosurg . 2021; 16 :457doi: 10.4103/ajns.AJNS_406_20 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 26.
Nannoni S, de Groot R, Bell S, Markus HS. Stroke in COVID-19: a systematic review and meta-analysis
. Int J Stroke . 2021; 16 :137''149. doi: 10.1177/1747493020972922 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 27.
Khan F, Sharma P, Pandey S, Sharma D, Kumar N, Shukla S, et al. COVID'19'associated Guillain'Barre syndrome: Postinfectious alone or neuroinvasive too?
J Med Virol . 2021; 93 :6045''6049. doi: 10.1002/jmv.27159 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 28.
Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank
. Nature . 2022; 604 :697''707. doi: 10.1038/s41586-022-04569-5 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 29.
Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease
. Nat Med . 2004; 10 ( Suppl ):S10''S17. doi: 10.1038/nm1066 [PubMed] [CrossRef] [Google Scholar] 30.
Sun B, Tang N, Peluso MJ, Iyer NS, Torres L, Donatelli JL, et al. Characterisation and biomarker analyses of post-covid-19 complications and neurological manifestations
. Cells . 2021; 10 :386. doi: 10.3390/cells10020386 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 31.
Idrees D, Kumar V. SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration
. Biochem Biophys Res Commun . 2021; 554 :94''98. doi: 10.1016/j.bbrc.2021.03.100 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 32.
Tavassoly O, Safavi F, Tavassoly I. Seeding brain protein aggregation by SARS-CoV-2 as a possible long-term complication of COVID-19 infection
. ACS Chem Neurosci . 2020; 11 :3704''3706. doi: 10.1021/acschemneuro.0c00676 [PubMed] [CrossRef] [Google Scholar] 33.
Ramani A, M¼ller L, Ostermann PN, Gabriel E, Abida'Islam P, M¼ller'Schiffmann A, et al. SARS'CoV'2 targets neurons of 3D human brain organoids
. EMBO J . 2020; 39 :p.e106230. doi: 10.15252/embj.2020106230 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 34.
Quinn JP, Corbett NJ, Kellett KA, Hooper NM. Tau proteolysis in the pathogenesis of tauopathies: neurotoxic fragments and novel biomarkers
. J Alzheimer's Dis . 2018; 63 :13''33doi: 10.3233/JAD-170959 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 35.
Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, Subramaniam V. Dependence of α-synuclein aggregate morphology on solution conditions
. J Mol Biol . 2002; 322 :383''393. doi: 10.1016/S0022-2836(02)00775-1 [PubMed] [CrossRef] [Google Scholar] 36.
Margittai M, Langen R. Template-assisted filament growth by parallel stacking of tau
. Proc Natl Acad Sci USA . 2004; 101 :10278''10283. doi: 10.1073/pnas.0401911101 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 37.
Bl¶meke L, Pils M, Kraemer-Schulien V, Dybala A, Schaffrath A, Kulawik A, et al. Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting
. NPJ Parkinsons Dis . 2022; 8 :1''13. doi: 10.1038/s41531-022-00330-x [PMC free article] [PubMed] [CrossRef] [Google Scholar] 38.
Eberle RJ, Olivier DS, Amaral MS, Gering I, Willbold D, Arni RK, et al. The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CLproIn Vitro . Viruses . 2021; 13 :873. doi: 10.3390/v13050873 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 39.
Kravchenko K, Kulawik A, H¼lsemann M, K¼hbach K, Zafiu C, Herrmann Y, et al. Analysis of anticoagulants for blood-based quantitation of amyloid β oligomers in the sFIDA assay
. Biol Chem . 2017; 398 :465''75. doi: 10.1515/hsz-2016-0153 [PubMed] [CrossRef] [Google Scholar] 40.
Herrmann Y, Bujnicki T, Zafiu C, Kulawik A, K¼hbach K, Peters L, et al. Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies
. Clin Chim . 2017; 466 :152''159. doi: 10.1016/j.cca.2017.01.010 [PubMed] [CrossRef] [Google Scholar] 41.
H¼lsemann M, Zafiu C, K¼hbach K, L¼hmann N, Herrmann Y, Peters L, et al. Biofunctionalised silica nanoparticles: standards in amyloid-β oligomer-based diagnosis of Alzheimer's disease
. J Alzheimer's Dis . 2016; 54 :79''88. doi: 10.3233/JAD-160253 [PubMed] [CrossRef] [Google Scholar] 42.
Goedert M, Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerisation
. EMBO J . 1990; 13 :4225''4230. doi: 10.1002/j.1460-2075.1990.tb07870.x [PMC free article] [PubMed] [CrossRef] [Google Scholar] 43.
Bachmann S, Bell M, Klimek J, Zempel H. Differential effects of the six human TAU isoforms: somatic retention of 2N-TAU and increased microtubule number induced by 4R-TAU
. Front Neurosci . 2021; 15 :643115. doi: 10.3389/fnins.2021.643115 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 44.
Yao TM, Tomoo K, Ishida T, Hasegawa H, Sasaki M, Taniguchi T. Aggregation analysis of the microtubule binding domain in tau protein by spectroscopic methods
. J Biochem (Tokyo) . 2003; 134 :91''99. doi: 10.1093/jb/mvg116 [PubMed] [CrossRef] [Google Scholar] 45.
von Bergen M, Barghorn S, Biernat J, Mandelkow EM, Mandelkow E. Tau aggregation is driven by a transition from random coil to beta sheet structure
. Biochim Biophys Acta BBA Mol Basis Dis . 2005; 1739 :158''166. doi: 10.1016/j.bbadis.2004.09.010 [PubMed] [CrossRef] [Google Scholar] 46.
Karikari TK, Turner A, Stass R, Lee LCY, Wilson B, Nagel DA, et al. Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag
. Protein Expr Purif . 2017; 130 :44''54. doi: 10.1016/j.pep.2016.09.009 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 47.
Barghorn S, Zheng-Fischh¶fer Q, Ackmann M, Biernat J, von Bergen M, Mandelkow EM, et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias
. Biochemistry . 2000; 39 :11714''11721. doi: 10.1021/bi000850r [PubMed] [CrossRef] [Google Scholar] 48.
Luo J, He R, Li W. The fluorescent characterisation of the polymerised microtubule-associated protein Tau
. Int J Biol Macromol . 2000; 27 :263''268. doi: 10.1016/S0141-8130(00)00126-4 [PubMed] [CrossRef] [Google Scholar] 49.
Chirita CN, Necula M, Kuret J. Anionic micelles and vesicles induce tau fibrillisation in vitro
. J Biol Chem . 2003; 278 :25644''50. doi: 10.1074/jbc.M301663200 [PubMed] [CrossRef] [Google Scholar] 50.
Ait-Bouziad N, Mahul-Mellier AL, Xiao S, Zorludemir G, Eliezer D, Walz T, et al. Discovery and characterisation of stable and toxic Tau/phospholipid oligomeric complexes
. Nat Commun . 2017; 8 :1678. doi: 10.1038/s41467-017-01575-4 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 51.
Lobo-Galo N, Terrazas-L"pez M, Martnez-Martnez A, Daz-Snchez G. FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication
. J Biomol Struct Dyn . 2021; 39 :3419''3427. doi: 10.1080/07391102.2020.1764393 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 52.
Rawlings ND, Barrett AJ, Thomas PD, Huang X, Bateman A, Finn RD. The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database
. Nucleic Acids Res . 2018; 46 ( D1 ):D624''D632. doi: 10.1093/nar/gkx1134 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 53.
Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, et al. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease
. J Neurosci . 2004; 24 :7895''7902. doi: 10.1523/JNEUROSCI.1988-04.2004 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 54.
Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation
. Proc Natl Acad Sci USA . 2006; 103 :2892''2897. doi: 10.1073/pnas.0511065103 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 55.
Park SY, Ferreira A. The generation of a 17 kDa neurotoxic fragment: An alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration
. J Neurosci . 2005; 25 :5365''5375. doi: 10.1523/JNEUROSCI.1125-05.2005 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 56.
Garg S, Timm T, Mandelkow EM, Mandelkow E, Wang Y. Cleavage of Tau by calpain in Alzheimer's disease: The quest for the toxic 17 kD fragment
. Neurobiol Aging . 2010; 32 :1''14. doi: 10.1016/j.neurobiolaging.2010.09.008 [PubMed] [CrossRef] [Google Scholar] 57.
Zhao X, Kotilinek LA, Smith B, Hlynialuk C, Zahs K, Ramsden M, et al. Caspase-2 cleavage of tau reversibly impairs memory
. Nat Med . 2016; 22 :1268''1276. doi: 10.1038/nm.4199 [PubMed] [CrossRef] [Google Scholar] 58.
Yang LS, Ksiezak-Reding H. Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments
. Eur J Biochem . 1995; 233 :9''17. doi: 10.1111/j.1432-1033.1995.009_1.x [PubMed] [CrossRef] [Google Scholar] 59.
Matsumoto SE, Motoi Y, Ishiguro K, Tabira T, Kametani F, Hasegawa M, et al. The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: Implications of prion-like properties
. Hum Mol Genet . 2015; 24 :6403''6416. doi: 10.1093/hmg/ddv351 [PubMed] [CrossRef] [Google Scholar] 60.
Henriksen K, Wang Y, Sorensen MG, Barascuk N, Suhy J, Pedersen JT, et al. An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function
. PLoS One . 2013; 8 :e64990. doi: 10.1371/journal.pone.0064990 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 61.
Arai T, Guo JP, McGeer PL. Proteolysis of non-phosphorylated and phosphorylated tau by thrombin
. J Biol Chem . 2005; 280 :5145''5153. doi: 10.1074/jbc.M409234200 [PubMed] [CrossRef] [Google Scholar] 62.
Steiner B, Mandelkow EM, Biernat J, Gustke N, Meyer HE, Schmidt B, et al. Phosphorylation of microtubule-associated protein tau: Identification of the site for Ca2(+)-calmodulin dependent kinase and relationship with tau phosphorylation in Alzheimer tangles
. EMBO J . 1990; 9 :3539''3544. doi: 10.1002/j.1460-2075.1990.tb07563.x [PMC free article] [PubMed] [CrossRef] [Google Scholar] 63.
Zhang Z, Song M, Liu X, Kang SS, Kwon IS, Duong DM, et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease
. Nat Med . 2014; 20 :1254''1262. doi: 10.1038/nm.3700 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 64.
Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, et al. Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease
. Proc Natl Acad Sci USA . 2003; 100 :10032''10037. doi: 10.1073/pnas.1630428100 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 65.
Alam P, Bousset L, Melki R, Otzen DE. Alpha-synuclein oligomers and fibrils: A spectrum of species, a spectrum of toxicities
. J Neurochem . 2019; 150 :522''534. doi: 10.1111/jnc.14808 [PubMed] [CrossRef] [Google Scholar] 66.
Sengupta U, Portelius E, Hansson O, Farmer K, Castillo'Carranza D, Woltjer R, et al. Tau oligomers in cerebrospinal fluid in Alzheimer's disease
. Ann Clin Transl Neurol . 2017; 4 :226''235. doi: 10.1002/acn3.382 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 67.
Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
. Lancet Glob Health . 2022; 7 :e105''e125. doi: 10.1016/S2468-2667(21)00249-8 [PMC free article] [PubMed] [CrossRef] [Google Scholar] This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
19 Apr 2023
PONE-D-23-07828Tau protein aggregation associated with SARS-CoV-2 main proteasePLOS ONE
Dear Dr. Raphael J. Eberle,
Thank you for submitting your manuscript to PLOS ONE. After its careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that convincingly addresses the all points raised by both reviewers. Please submit your revised manuscript by July 1st. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at gro.solp@enosolp. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
Please include the following items when submitting your revised manuscript:
A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.
We look forward to receiving your revised manuscript.
Kind regards,
Maria Gasset, Ph.D.
Academic Editor
PLOS ONE
Journal Requirements:
When submitting your revision, we need you to address these additional requirements.
1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and
https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf
2. We note that the grant information you provided in the 'Funding Information' and 'Financial Disclosure' sections do not match.
When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the 'Funding Information' section.
[Note: HTML markup is below. Please do not edit.]
Reviewers' comments:
Reviewer's Responses to Questions
Comments to the Author
1. Is the manuscript technically sound, and do the data support the conclusions?
The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
Reviewer #1: Yes
Reviewer #2: Yes
**********
2. Has the statistical analysis been performed appropriately and rigorously?
Reviewer #1: N/A
Reviewer #2: Yes
**********
3. Have the authors made all data underlying the findings in their manuscript fully available?
The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data'--e.g. participant privacy or use of data from a third party'--those must be specified.
Reviewer #1: Yes
Reviewer #2: Yes
**********
4. Is the manuscript presented in an intelligible fashion and written in standard English?
PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
Reviewer #1: Yes
Reviewer #2: No
**********
5. Review Comments to the Author
Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)
Reviewer #1: The work presented by Eberle et al. presents novel discoveries of interest to the field of SARS-CoV-2-host interaction, as well as broader implications to the field of neurodegeneration due to the generation of an aggregation-prone truncation of tau by one of the virus proteases.
The authors provide in vitro evidence for a possible triggering mechanism for tau aggregation induced by the SARS-CoV-2 3CL protease (3CLpro), which would cleave full-length tau to generate a pool of fragments, one or more of which would efficiently aggregate. Despite the lack of a more detailed study on the exact cleaving site, the identification of the aggregation-prone fragment, and cell-based studies to better understand the findings, their main claim is justified and supported by the biophysical analysis in the paper. Specifically, Eberle et al. used ThT assays, analytical HPLC and mass spectrometry to report the effect of 3CLpro on tau cleavage and subsequent aggregation. Despite the abovementioned missed points that could improve its appeal to a broader audience, this study provides informative results and interpretations suitable for publication in PLOS ONE, subject to the suggested revisions mentioned below:
Major concerns:
1. The abstract may be misleading as it suggests that the study involves all three proteins (tau, TDP-43, and alpha-synuclein) when, in fact, its focus is only on tau. It would be clearer to specify that this study investigates the effects of 3CLpro on tau aggregation, rather than mentioning TDP-43 and alpha-synuclein which were not affected.
2. The results of this study indicate that 3CLpro proteolytically cleaves 2N4R tau and the cleavage is associated with tau aggregation events. However, it would be beneficial to get a more detailed picture, such as which fragment (or at least which peak observed in HPLC analysis) aggregates, by performing ThT assays on the different fractions obtained upon digestion and HPLC analysis.
Minor concerns:
1. On page 8, line 237, it states that "2N4R tau consists of 266 amino acids with an approximated molecular weight of 46 kDa." However, 2N4R tau is the largest size human brain tau and is composed of 441 amino acids in length; this should be corrected/clarified.
2. Although the analysis of alpha-syn and TDP43 is limited, an SDS-PAGE should be included to assess their sample quality and purity, as done for 2N4R tau in Figure S1.
3. The Western Blotting with CF633 labeled tau13 in Figure S2A (lane 2) should be improved as it shows almost no reactivity.
4. In Figure S2B, a control should be included to show whether heparin on its own contributes to the CD spectrum. Furthermore, the specific method section for CD is missing and should be added, explaining how heparin signal is subtracted from the experimental data during the data processing and analysis.
5. In Figure S2B, the light gray CD spectrum is claimed to correspond to "2N4R tau filament". Imaging analysis (AFM or TEM) should be performed to support this claim.
6. In the legend of Figure 1B (page 9, lines 263-264), it is claimed that "The inactivation of the protease was treated with 10 µM DSF". However, the inactivation condition is reported in Figure 1C, so this should be corrected.
7. On page 9, lines 271-272, it is claimed that "the monomer concentration and its cleavage are accompanied by the amount of aggregate formation (S3B Fig)". However, this observation could be due to the increased concentration of monomer which, even without being cleaved, could aggregate efficiently. In order to support this assertion, the same assay should be performed in the presence of DSF-inactivated protease.
8. In Figure 1D, it is unclear why the fluorescence intensity decreases upon protease deactivation. If aggregates were already formed, the fluorescence intensity should remain unaltered. The decrease could suggest that the formed aggregates can be disassembled or degraded upon inhibitor addition. To clarify this point, a control consisting of aggregated tau (i.e., induced by heparin) + DSF (without protease) should be included to control the potential effect of the inhibitor itself.
9. The two gels shown in Figure 2C should not be cropped and should ideally be shown in a single gel to observe the concomitant decrease of the full-length tau associated with the increase of the 25kDa fragment.
10. As stated in Fig. 4D, "tau samples containing active 3CLpro yielded higher aggregate-specific readouts than tau samples in presence of inactivated protease". However, the readout appears to be quite similar, and a statistical test should be included to support the conclusions.
Reviewer #2: This manuscript describes studies aimed at evaluating the possible induction of protein aggregation by the SARS-CoV-2 3CL protease (3CLpro), which might be relevant in explaining the long term neuropathology induced by infection by this virus.
The Authors performed a series of simple, classic, clear-cut in vitro biochemistry studies based on mixing recombinant tau and 3CLpro and following their interaction using SDS-PAGE and HPLC (to detect fragmentation), or thioflavin fluorescence (to follow aggregation), under different concentration-dependence and kinetic regimens. Mass spectrometry was used to further identify the fragments of tau produced by 3CLpro. Lack of effect of 3CLpro on other proteins relevant to neuropathology, such as synuclein, was also established by similar approaches.
All these experiments were carefully executed, and adequate controls included. Of course, given the high prevalence of neurological ailments within "persistent Covid-19", this line of research is of potential interest.
Having stated this, I find two shortcomings in the manuscript:
1) The ratio of substrate to protease used in these experiments was very high, with a maximum effect when equimolar (10 uM) concentrations were used. Increasing this ratio, to 5, or even 2...resulted in a very substantial decrease of the effect. This casts doubts on the physiological relevance of the results, something that is not acknowledged or discussed by the Authors. Do they envision a set of physiological conditions in which the intracellular or extracellular concentration of 3CLpro are sufficient to cleave tau and cause its aggregation during SARS-Cov-2 infection? Furthermore, the majority of neurological complications of Covid-19 are relatively acute, whereas tau aggregation is involved in neurodegenerative processes (for example, Alzheimer´s disease) which take many years to develop. How do the Authors link a putative 3CLpro-induced aggregation of tau with specific SARS-Cov-2-linked neurological pathology?
2) The manuscript is written in an amateurish fashion (I apologize if the term seems too negative, it is meant to be merely descriptive). A few examples: bullets in the Conclusion section; "Different dementias show a conformationally altered concentration of tau" (a concentration can be high or low, but not "conformationally altered" (line 384); Table 3 in the Discussion, rather than a narrative description of its contents; "...tryptic tau peptides are no longer detectable by 3CLpro into different fragments..." (I understand the Authors mean that 3CLPro, under these experimental conditions, does not generate fragments that, after tryptic digestion, are amenable of identification...)(line 335); Analysis of the tau digestion underwent 3CLpro using mass spectrometrY (????) (line 313); "HPLC experiments with 2N4R tau and inactivated 3CLpro showed that the corresponding tau peak and the peak regions I, II and III are unaffected" (the Authors mean kinetic experiments, HPLC is just an analytical tool, not an experimental approach or design...) (line 310). And many other examples.
Finally, I would suggest analyzing peak I and peak ensembles (they are not "individual peaks") II, and III also directly, withouth prior tryptic digestion. That might allow establishing the size of the different 3CLpro fragments generated, and by combining that information with the sequence of their tryptic fragments (combined, in the case of II and III) their complete characterization.
**********
6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.
If you choose ''no'', your identity will remain anonymous but your review may still be made public.
Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.
Reviewer #1: No
Reviewer #2: No
**********
[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]
While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at gro.solp@serugif. Please note that Supporting Information files do not need this step.
8 Jun 2023
Journal Requirements
Comment 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.
Response 1. We checked all submitted files and corrected them accordingly.
Comment 2. We note that the grant information you provided in the 'Funding Information' and 'Financial Disclosure' sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the 'Funding Information' section.
Response 2. We corrected accordingly.
Changes by the authors
' We included negative staining Transmission Electron Microscopy (TEM) pictures of the Tau filaments after treatment of 3CLpro. Accordingly we included material and methods, results, new Fig2 and S6 Fig.
' We added one Co-author, Simon Sommerhage, who's performed the TEM experiments.
Reviewer 1
Comment 1. The abstract may be misleading as it suggests that the study involves all three proteins (tau, TDP-43, and alpha-synuclein) when, in fact, its focus is only on tau. It would be clearer to specify that this study investigates the effects of 3CLpro on tau aggregation, rather than mentioning TDP-43 and alpha-synuclein which were not affected.
Response 1. We changed accordingly
Comment 2. The results of this study indicate that 3CLpro proteolytically cleaves 2N4R tau and the cleavage is associated with tau aggregation events. However, it would be beneficial to get a more detailed picture, such as which fragment (or at least which peak observed in HPLC analysis) aggregates, by performing ThT assays on the different fractions obtained upon digestion and HPLC analysis.
Response 2. We agree with the reviewer's comment. However, preparing the samples for the HPLC analyses includes incubation of tau by 3CLpro, at 37°C for 24h to 72h. After the incubation, we observed significant protein aggregates in the solution, and before applying it to HPLC, we centrifuged the sample to separate aggregates from soluble tau fractions. Consequently, the peak fractions after the HPLC contain soluble tau fragments that are not aggregated. We added a statement in the related material and method section to describe the procedure (lines 181 to 182).
Minor concerns:
Comment 1. On page 8, line 237, it states that "2N4R tau consists of 266 amino acids with an approximated molecular weight of 46 kDa." However, 2N4R tau is the largest size human brain tau and is composed of 441 amino acids in length; this should be corrected/clarified.
Response 1. We corrected accordingly, 266 to 241 amino acids.
Comment 2. Although the analysis of alpha-syn and TDP43 is limited, an SDS-PAGE should be included to assess their sample quality and purity, as done for 2N4R tau in Figure S1.
Response 2. We added SDS pages for TDP43 and alpha-synuclein purification to demonstrate the purity and quality of the proteins. The SDS pages are shown in S4 Fig.
Comment 3. The Western Blotting with CF633 labeled tau13 in Figure S2A (lane 2) should be improved as it shows almost no reactivity.
Response 3. We added a new western blot in Figure S2A (lane 2).
Comment 4. In Figure S2B, a control should be included to show whether heparin on its own contributes to the CD spectrum. Furthermore, the specific method section for CD is missing and should be added, explaining how heparin signal is subtracted from the experimental data during the data processing and analysis.
Response 4. We added the CD spectrum of 2.5 µM heparin, which showed no signal in the measured wavelength range (190-240 nm). As described in the material and methods section, this heparin concentration was used to induce tau aggregation. We also added a CD spectrum of a tenfold higher heparin concentration (25 µM), which demonstrated a minimum in the CD spectra at 220 nm. However, the heparin concentration used for tau aggregation (2.5 µM) showed no signal on the CD-spectrum, demonstrated in the new S3 Figure and a statement in the results lines 284 to 287. Additionally, we added the missing CD method section.
Comment 5. In Figure S2B, the light gray CD spectrum is claimed to correspond to "2N4R tau filament". Imaging analysis (AFM or TEM) should be performed to support this claim.
Response 5. It is well established that CD can be used to follow tau aggregation as the process accompanies a transition from an unfolded structure to a partially folded structure with approximately 36% of β-sheet. The CD spectra show this typical shift from an unfolded structure (around 200 nm) to a structure containing β-sheet (around 220).
This observation is described in various publications, and a few examples is mentioned in the reference list:
' https://doi.org/10.1021/bi0357006
' https://doi.org/10.1016/j.bbadis.2004.09.010
' https://doi.org/10.1016/j.pep.2016.09.009
Comment 6. In the legend of Figure 1B (page 9, lines 263-264), it is claimed that "The inactivation of the protease was treated with 10 µM DSF". However, the inactivation condition is reported in Figure 1C, so this should be corrected.
Response 6. We corrected accordingly
Comment 7. On page 9, lines 271-272, it is claimed that "the monomer concentration and its cleavage are accompanied by the amount of aggregate formation (S3B Fig)". However, this observation could be due to the increased concentration of monomer which, even without being cleaved, could aggregate efficiently. In order to support this assertion, the same assay should be performed in the presence of DSF-inactivated protease.
Response 7. Control experiments were performed with different tau concentrations in the absence of the protease to demonstrate that there is no concentration-dependent in the aggregation process. We added the control experiments to Figure S5B.
Comment 8. In Figure 1D, it is unclear why the fluorescence intensity decreases upon protease deactivation. If aggregates were already formed, the fluorescence intensity should remain unaltered. The decrease could suggest that the formed aggregates can be disassembled or degraded upon inhibitor addition. To clarify this point, a control consisting of aggregated tau (i.e., induced by heparin) + DSF (without protease) should be included to control the potential effect of the inhibitor itself.
Response 8. Thanks for this comment. We corrected it accordngly.
Comment 9. The two gels shown in Figure 2C should not be cropped and should ideally be shown in a single gel to observe the concomitant decrease of the full-length tau associated with the increase of the 25kDa fragment.
Response 9. Fig 2C was changed accordingly.
Comment 10. As stated in Fig. 4D, "tau samples containing active 3CLpro yielded higher aggregate-specific readouts than tau samples in presence of inactivated protease". However, the readout appears to be quite similar, and a statistical test should be included to support the conclusions.
Response 10.
We changed the sentence accordingly. New statements were written in the results section, ''Compared to the tau aggregate control, however, only a small fraction of the employed tau substrate was converted into aggregates''. We also mentioned in conclusion, ''Adjustment and optimisation of sFIDA assay need to be performed to get meaningful results using this technique.
We changed the questionable sentence to ''tau samples containing active 3CLpro yielded a similar aggregate-specific readout compared with tau samples in the presence of inactivated protease''.
Reviewer 2
Comment 1. The ratio of substrate to protease used in these experiments was very high, with a maximum effect when equimolar (10 uM) concentrations were used. Increasing this ratio, to 5, or even 2...resulted in a very substantial decrease of the effect. This casts doubts on the physiological relevance of the results, something that is not acknowledged or discussed by the Authors. Do they envision a set of physiological conditions in which the intracellular or extracellular concentration of 3CLpro are sufficient to cleave tau and cause its aggregation during SARS-Cov-2 infection? Furthermore, the majority of neurological complications of Covid-19 are relatively acute, whereas tau aggregation is involved in neurodegenerative processes (for example, Alzheimer´s disease) which take many years to develop. How do the Authors link a putative 3CLpro-induced aggregation of tau with specific SARS-Cov-2-linked neurological pathology?
Response 1. We agree with the reviewer. However, this manuscript intended to demonstrate the potential of SARS-CoV-2 3CLpro to cleave tau in vitro and that this cleavage can induce aggregation of tau under the tested conditions. We need more experiments to get information about the physiological relevance and involvement in neurodegeneration. We are not claiming that SARS-CoV-2 3CLpro can induce neurodegenerative processes in vivo after a SARS-CoV-2 infection. For such a statement, we need specific experiments not conducted so far. We changed the conclusion accordingly to state that more experiments are necessary under physiological conditions and for an extended period.
However, two studies could connect COVID-19 infections with neurodegenerative processes:
' https://doi.org/10.3390/cells10020386
' https://doi.org/10.15252/embj.2020106230
We mentioned both studies in the introduction (References 30 and 33).
Comment 2. The manuscript is written in an amateurish fashion (I apologise if the term seems too negative, it is meant to be merely descriptive). A few examples: bullets in the Conclusion section; "Different dementias show a conformationally altered concentration of tau" (a concentration can be high or low, but not "conformationally altered" (line 384); Table 3 in the Discussion, rather than a narrative description of its contents; "...tryptic tau peptides are no longer detectable by 3CLpro into different fragments..." (I understand the Authors mean that 3CLPro, under these experimental conditions, does not generate fragments that, after tryptic digestion, are amenable of identification...)(line 335); Analysis of the tau digestion underwent 3CLpro using mass spectrometrY (????) (line 313); "HPLC experiments with 2N4R tau and inactivated 3CLpro showed that the corresponding tau peak and the peak regions I, II and III are unaffected" (the Authors mean kinetic experiments, HPLC is just an analytical tool, not an experimental approach or design...) (line 310). And many other examples.
Response 2. Several changes were made in the manuscript accordingly to reviwers suggestions.
Comment 3. Finally, I would suggest analysing peak I and peak ensembles (they are not "individual peaks") II, and III also directly, without prior tryptic digestion. That might allow establishing the size of the different 3CLpro fragments generated, and by combining that information with the sequence of their tryptic fragments (combined, in the case of II and III) their complete characterisation.
Response 3. The mass spectrometric experiments of the peaks aimed to confirm that they contain different tau species (Fragments) generated by the 3CLpro activity. As mentioned, it is the first finding on the role of the main protease in tau cleavage and aggregation. We will undoubtedly perform new experiments to obtain a detailed view of the tau fragments.
This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
20 Jun 2023
Tau protein aggregation associated with SARS-CoV-2 main protease
PONE-D-23-07828R1
Dear Dr. Raphael J. Eberle,
We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.
Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.
An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at gro.solp@gnillibrohtua.
If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact gro.solp@sserpeno.
Kind regards,
Maria Gasset, Ph.D.
Academic Editor
PLOS ONE
Additional Editor Comments (optional):
Reviewers' comments:
Reviewer's Responses to Questions
Comments to the Author
1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the ''Comments to the Author'' section, enter your conflict of interest statement in the ''Confidential to Editor'' section, and submit your "Accept" recommendation.
Reviewer #1: All comments have been addressed
**********
2. Is the manuscript technically sound, and do the data support the conclusions?
The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
Reviewer #1: Yes
**********
3. Has the statistical analysis been performed appropriately and rigorously?
Reviewer #1: N/A
**********
4. Have the authors made all data underlying the findings in their manuscript fully available?
The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data'--e.g. participant privacy or use of data from a third party'--those must be specified.
Reviewer #1: Yes
**********
5. Is the manuscript presented in an intelligible fashion and written in standard English?
PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
Reviewer #1: Yes
**********
6. Review Comments to the Author
Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)
Reviewer #1: I am delighted to announce that I have thoroughly reviewed the submitted manuscript and all my comments and concerns have been addressed by the authors. After consideration, I recommend the publication of this paper in PLOS ONE. The authors have diligently responded to the reviewers' feedback, implementing necessary revisions and improvements to enhance the quality and clarity of their work.
**********
7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.
If you choose ''no'', your identity will remain anonymous but your review may still be made public.
Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.
Reviewer #1: No
**********
This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
11 Aug 2023
PONE-D-23-07828R1
Tau protein aggregation associated with SARS-CoV-2 main protease
Dear Dr. Eberle:
I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.
If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact gro.solp@sserpeno.
If we can help with anything else, please email us at gro.solp@enosolp.
Thank you for submitting your work to PLOS ONE and supporting open access.
Kind regards,
PLOS ONE Editorial Office Staff
on behalf of
Dr. Maria Gasset
Academic Editor
PLOS ONE
Articles from PLOS ONE are provided here courtesy of PLOS